Trial
NCT02827513
A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Adult Attention-deficit Hyperactivity Disorder (ADHD)
Intervention
CTN SR1
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-18